Zy Therapeutics will convene its 2025 Scientific Advisory Board (SAB) meeting during the American Epilepsy Society (AES) Annual Meeting on Friday, December 5, 2025, in Atlanta, Georgia.
This Scientific Advisory Board meeting will bring together leading clinicians, researchers, and experts in rare epilepsies to review the company’s development program for Kamini® (disodium etidronate)—a first-in-class therapeutic candidate for Sturge-Weber Syndrome (SWS) and related refractory seizure disorders.
